An Open-label, Single-arm Phase II Study in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) to Evaluate Efficacy and Safety of Treatment With Single Agent Copanlisib and the Impact of Biomarkers Thereupon.
To assess the potential efficacy (in terms of objective response) of single agent copanlisib
in patients with relapsed or refractory Diffuse large B-cell lymphoma (DLBCL) and assess the
relationship between efficacy and a potentially predictive biomarker
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society